1Mathijssen R H,Marsh S,Karlsson M O,et al.Irinotecan pathway genotype analysis to predict pharmacokinetics[J].Clin Cancer Res,2003,15(9):3246-3253. 被引量:1
2Mathijssen R H,van Alphen R J,Verweij J,et al.Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)[J].Clinical Cancer Research 2001,7(9):2182-2194. 被引量:1
3Chabot G G,Abrigerges D,Catimel G,et al.Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phaseⅠtrials[J].Ann Oncol,1995,6(2):141-151. 被引量:1
4Michael M,Brittain M,Nagai J,et al.Phase Ⅱ study of activated charcoal to prevent irinotecan-Induced diarrhea[J].J Clin Oncol,2004,22(21):4410-4417. 被引量:1
5De Jong F A,Kehrer D F,Mathijssen R H,et al.Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening:a double-blind,randomized,placebo-controlled study[J].Oncologist,2006,11(8):944-954. 被引量:1
6Innocenti F,Kroetz D L,Schuetz E,et al.Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics[J].J Clin Oncol,2009,27(16):2604-2614. 被引量:1
7Khne C H,Cutsem E,Wils J,et al.Phase Ⅲ study of weekly high-dose infusional fluorouracil plus folinic acid with or without Irinotecan in patients with metastatic colorectal cancer:european organisation for research and treatment of cancer gastrointestinal group study 40986[J].J Clin Oncol,2005,23(22):4856-4865. 被引量:1
8Recchia F,Saggio G,Nuzzo A,et al.Multicentre phase Ⅱ study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX[J].Br J Cancer,2004,91(8):1442-1446. 被引量:1
9[1]VANHOEFER U,HARSTRICK A,KOHNE CH,et al.Phase Ⅰstudy of a weekly schedule of irinotecan,high-dose leucovorin,and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer[J].J Clin Oncol,1999,17(3):907-913. 被引量:1
10[2]DUCREUX M,YCHOU M,SEITZ JF,et al.Irinotecan combined with bolus fluorouracil,continuous infusion fluorouracil,and high-dose leucovorin every two weeks (LV5FUZ regimen):a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colcorectal cancer[J].J Clin Oncol,1999,17(9):2901-2908. 被引量:1